Immunome (NASDAQ:IMNM – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Immunome to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.
Insider and Institutional Ownership
44.6% of Immunome shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Immunome and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | N/A | -51.33% | -47.63% |
| Immunome Competitors | -12,519.20% | -215.47% | -31.42% |
Risk & Volatility
Immunome has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, Immunome’s competitors have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Immunome and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 1 | 1 | 14 | 0 | 2.81 |
| Immunome Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Immunome currently has a consensus price target of $33.85, suggesting a potential upside of 115.99%. As a group, “Biotechnology” companies have a potential upside of 114.70%. Given Immunome’s stronger consensus rating and higher probable upside, equities analysts plainly believe Immunome is more favorable than its competitors.
Valuation & Earnings
This table compares Immunome and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Immunome | N/A | -$212.39 million | -5.94 |
| Immunome Competitors | $751.08 million | $10.42 million | -17.98 |
Immunome’s competitors have higher revenue and earnings than Immunome. Immunome is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Immunome beats its competitors on 7 of the 13 factors compared.
About Immunome
Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
